BIOL Stock Overview
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BIOLASE, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$33.44 |
| 52 Week Low | US$0.13 |
| Beta | 0.69 |
| 1 Month Change | 6.07% |
| 3 Month Change | -83.22% |
| 1 Year Change | -99.51% |
| 3 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24
BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?
Jul 14Biolase shares jump 11% after regaining Nasdaq compliance
Feb 04Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined
Feb 01BIOLASE's (NASDAQ:BIOL) Stock Price Has Reduced 78% In The Past Five Years
Jan 24
BIOLASE strikes deal with Dental Care Alliance in laser adoption push
Jan 12Health Check: How Prudently Does BIOLASE (NASDAQ:BIOL) Use Debt?
Dec 02Shareholder Returns
| BIOL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.6% | -4.4% | -3.7% |
| 1Y | -99.5% | -2.8% | 20.2% |
Return vs Industry: BIOL underperformed the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: BIOL underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| BIOL volatility | |
|---|---|
| BIOL Average Weekly Movement | 25.8% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOL's share price has been volatile over the past 3 months.
Volatility Over Time: BIOL's weekly volatility has increased from 20% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 157 | John Beaver | www.biolase.com |
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production.
BIOLASE, Inc. Fundamentals Summary
| BIOL fundamental statistics | |
|---|---|
| Market cap | US$4.83m |
| Earnings (TTM) | -US$37.62m |
| Revenue (TTM) | US$49.16m |
0.1x
P/S Ratio-0.1x
P/E RatioIs BIOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOL income statement (TTM) | |
|---|---|
| Revenue | US$49.16m |
| Cost of Revenue | US$32.44m |
| Gross Profit | US$16.72m |
| Other Expenses | US$54.34m |
| Earnings | -US$37.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 34.02% |
| Net Profit Margin | -76.52% |
| Debt/Equity Ratio | 718.1% |
How did BIOL perform over the long term?
See historical performance and comparison